2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

Andrus, Bruce; Lacaille, Diane

doi:10.1016/j.jacc.2014.02.606

Cited by 107 publications

(86 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[18][19][20][21] The 2013 American College of Cardiology/American Heart Association (AHA) guidelines on assessment of CVD risk recommend the use of ASCVD risk calculator, which accounts for sex and ethnic diversity but not the emerging risk factors prevalent in women. 22 …”

Section: Risk Factorsmentioning

confidence: 99%

Sex Differences in Ischemic Heart Disease

Aggarwal

Patel

Mehta

et al. 2018

Circ: Cardiovascular Quality and Outcomes

226

View full text Add to dashboard Cite

Evolving knowledge of sex-specific presentations, improved recognition of conventional and novel risk factors, and expanded understanding of the sex-specific pathophysiology of ischemic heart disease have resulted in improved clinical outcomes in women. Yet, ischemic heart disease continues to be the leading cause of morbidity and mortality in women in the United States. The important publication by the Institute of Medicine titled "Women's Health Research-Progress, Pitfalls, and Promise," highlights the persistent disparities in cardiovascular disease burden among subgroups of women, particularly women who are socially disadvantaged because of race, ethnicity, income level, and educational attainment. These important health disparities reflect underrepresentation of women in research, with the resultant unfavorable impact on diagnosis, prevention, and treatment strategies in women at risk for cardiovascular disease. Causes of disparities are multifactorial and related to differences in risk factor prevalence, access to care, use of evidence-based guidelines, and social and environmental factors. Lack of awareness in both the public and medical community, as well as existing knowledge gap regarding sex-specific differences in presentation, risk factors, pathophysiology, and response to treatment for ischemic heart disease, further contribute to outcome disparities. There is a critical need for implementation of sex-and gender-specific strategies to improve cardiovascular outcomes. This review is tailored to meet the needs of a busy clinician and summarizes the contemporary trends, characterizes current sex-specific outcome disparities, delineates challenges, and proposes transformative solutions for improvement of the full spectrum of ischemic heart disease clinical care and research in women.by guest on May 7, 2018

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Sex Differences in Ischemic Heart Disease

Aggarwal

Patel

Mehta

et al. 2018

Circ: Cardiovascular Quality and Outcomes

226

View full text Add to dashboard Cite

show abstract

“…Around 66 consecutive acute coronary syndrome patients above 18 years with persistent ST elevation myocardial infarction based on the American College of Cardiology/ American Heart Association STEMI diagnosis guideline and Sgarbossa criteria for myocardial infarction in LBBB, presenting within 12 hours of symptom onset were included in present study. 4,5 Those patients whopresentedlate or with evidence of liverdisease, chronic kidney disease, and those suspected to have pulmonary thromboembolism were excluded from present study. 6 The recruited patients after signing the informed consent underwent a series of investigations such as Electrocardiography, Random blood sugar, Urea, Creatinine, liver function test estimation of cardiac biomarkers such as CK-MB, cardiac Troponin I (cTnI) using electro chemiluminescence immunoassay-2 antibodies sandwich principleand H-FABP by Enzyme Linked Immune Sorbent Assay (ELISA), based on biotin double antibody sandwich technology.…”

Section: Methodsmentioning

confidence: 99%

Diagnostic utility of heart type fatty acid binding protein (H-FABP) versus cardiac troponin I in myocardial infarction

et al. 2018

View full text Add to dashboard Cite

Background: Acute myocardial infarction (AMI) management is one of the therapeutic challenges faced by the emergency physician. In the field of investigational cardiology advancements, the search of superior cardiac biomarkers has led to the discovery of sensitive biomarkers which help in the early confirmation of MI as timely intervention is the primary goal in acute coronary syndrome (ACS). Present study was aimed to evaluate the diagnostic performance of the novel biomarker H- FABP in patients with AMI especially in ST elevation MI (STEMI) and comparison of its diagnostic accuracy with the other biomarkers.Methods: We studied 66 patients with persistent STEMI presenting within 12 hours of symptom to the department of General Medicine, Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Puducherry. Quantitative and qualitative estimation and analysis of serum biomarkers of acute myocardial infarction such as CK-MB, cardiac Troponin I (cTnI) and H-FABP were done.Results: The sensitivity and specificity of H-FABP were 80.7 and 88.9% respectively. The positive percentage of the serum biomarkers among these patients were 64%, 65%, 86% for CK-MB, cardiac troponin I, and H-FABP respectively. The area under the curve was observed to be 0.695, with 95% confidence interval (0.514-0.876) at the optimum cut-off value of 7.0ng/ml for H-FABP.Conclusions: H-FABP the novel biomarker, because of its early appearance in the blood stream and due to its superior sensitivity and specificity compared to Troponin I and CK-MB can be used in the early diagnosis of acute ST elevation Myocardial Infarction.

show abstract

“…In recent years, the American College of Cardiology (ACC) and the American Heart Association (AHA) have classified ischemic stroke as a atherosclerotic cardiovascular disease events60. We obtained known AIS drugs from the guideline designed by AHA and American Stroke Association (ASA) professionals6162.…”

Section: Methodsmentioning

confidence: 99%

Network-Based Approach to Identify Potential Targets and Drugs that Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Wang

Liu

Lin

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Acute ischemic stroke (AIS) accounts for more than 80% of the approximately 610,000 new stroke cases worldwide every year. Both ischemia and reperfusion can cause death, damage, and functional changes of affected nerve cells, and these alterations can result in high rates of disability and mortality. Therefore, therapies aimed at increasing neuroprotection and neurorepair would make significant contributions to AIS management. However, with regard to AIS therapies, there is currently a large gap between experimental achievements and practical clinical solutions (EC-GAP-AIS). Here, by integrating curated disease-gene associations and interactome network known to be related to AIS, we investigated the molecular network mechanisms of multi-module structures underlying AIS, which might be relevant to the time frame subtypes of AIS. In addition, the EC-GAP-AIS phenomenon was confirmed and elucidated by the shortest path lengths and the inconsistencies in the molecular functionalities and overlapping pathways between AIS-related genes and drug targets. Furthermore, we identified 23 potential targets (e.g. ADORA3, which is involved in the regulation of cellular reprogramming and the extracellular matrix) and 46 candidate drugs (e.g. felbamate, methylphenobarbital and memantine) that may have value for the treatment of AIS.

show abstract

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

Cited by 107 publications

References 3 publications

Sex Differences in Ischemic Heart Disease

Sex Differences in Ischemic Heart Disease

Diagnostic utility of heart type fatty acid binding protein (H-FABP) versus cardiac troponin I in myocardial infarction

Network-Based Approach to Identify Potential Targets and Drugs that Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Contact Info

Product

Resources

About